Immune-related adverse events of immune checkpoint inhibitors: a review
Open accessThe DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Abstract
Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved. Despite the success of immune checkpoint inhibitors, resistance limits the number of patients who can achieve a lasting response, and immune-related adverse events complicate treatment. The mechanism of immune-related adverse events (irAEs) is unclear. We summarize and discuss the mechanisms of action of immune checkpoint inhibitors, the different types of immune-related adverse events and their possible mechanisms, and describe possible strategies and targets for prevention and therapeutic interventions to mitigate them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046 · cited 1×
“IL6 is an inflammatory cytokine produced by various cells and participates in the pathogenesis of immune disorders, exerting multiple effects (136).”
BackgroundIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788 · cited 1×
“Further studies are needed for potential biomarkers useful to perform such prediction, such as mismatch repair (MMR) deficiency (122), interferon-g (IFN-g)-related mRNA profile (123), and T-cell invigoration to tumor burden ratio (124).”
BackgroundMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 1×
“Activated T cells can secrete a large number of cytokines to upregulate immune checkpoints (8, 9).”
BackgroundWang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,372
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · cited 3×
“Deletion of CTLA-4 and PD-1 lead to autoimmune myocarditis (56, 101, 102).”
BackgroundBagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.001 · Cited by 1,311
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211 · cited 2×
“Immune checkpoint blockade is designed to interfere with inhibitory pathways that naturally constrain T-cell reactivity, therefore releasing inherent limits on the activation and maintenance of T-cell effector function (28).”
BackgroundBarroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
COLEY, W. B. (1991) · PubMed · Cited by 965
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 939
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Freites-Martinez, A., Santana, N., Arias-Santiago, S., & Viera, A. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2019.05.009 · Cited by 889
Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
Self-citationWang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · cited 1×
“It can be induced on the cell surface, binds to CD80 (B7-1) and CD86 (B7-2) on the surface of antigen presenting cells (APCs), and has a higher affinity than the costimulatory molecule CD28 of T cells, thereby inhibiting cytotoxic T-cell activity and enhancing regulatory T-cell (Treg) immunosuppressive activity, causi…”
BackgroundBertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704 · cited 1×
“86% of patients dying due to irAEs (37).”
BackgroundPathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah, G. E., Brahmachari, S., Shin, J.-H., et al. (2016) · Science · doi:10.1126/science.aah3374 · Cited by 690
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Twomey, J. D., & Zhang, B. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00574-0 · Cited by 657
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 627
Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy
Sibaud, V. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0336-3 · Cited by 626
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., & Carpentier, A. F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.001 · Cited by 571
Drobni, Z. D., Alvi, R. M., Taron, J., Zafar, A., Murphy, S. P., Rambarat, P. K., Mosarla, R. C., Lee, C., Zlotoff, D. A., Raghu, V. K., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049981 · Cited by 560
Xu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 558
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
Clinical Challenges of Immune Checkpoint Inhibitors
de Miguel, M., & Calvo, E. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.004 · Cited by 540
Kouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30231-0 · Cited by 509
Fang, W., Yang, Y., Ma, Y., Hong, S., Lin, L., He, X., Xiong, J., Li, P., Zhao, H., Huang, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30495-9 · Cited by 489
De Velasco, G., Je, Y., Bossé, D., Awad, M. M., Ott, P. A., Moreira, R. B., Schutz, F., Bellmunt, J., Sonpavde, G. P., Hodi, F. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0237 · Cited by 486
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 485
Immune Checkpoint Inhibitors: Basics and Challenges
Li, B., Chan, H. L., & Chen, P. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170804143706 · Cited by 480
Immune checkpoint inhibitor–related dermatologic adverse events
Geisler, A. N., Phillips, G. S., Barrios, D. M., Wu, J., Leung, D. Y. M., Moy, A. P., Kern, J. A., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.132 · Cited by 480
Wang, P.-F., Chen, Y., Song, S.-Y., Wang, T.-J., Ji, W.-J., Li, S.-W., Liu, N., & Yan, C.-X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00730 · Cited by 468
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441 · cited 1×
“Organs most commonly affected by ICI-related endocrine toxicity include the thyroid gland (which typically manifests as hypothyroidism, often secondary to thyroiditis; Graves’ disease-like hyperthyroidism is very rare), pituitary gland (hypophysitis or hypopituitarism), and islet beta cells (presentation similar to ty…”
BackgroundBimekizumab versus Secukinumab in Plaque Psoriasis
Reich, K., Warren, R. B., Lebwohl, M., Gooderham, M., Strober, B., Langley, R. G., Paul, C., De Cuyper, D., Vanvoorden, V., Madden, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102383 · Cited by 424
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381 · cited 1×
“Primary hypothyroidism occurs in 6%–9% of patients treated with anti-PD-1 and/or antiPD-L1, 4%–9% of patients treated with anti-CTLA-4, and approximately 16% of patients treated with anti-PD-1 (L)-1 and anti-CTLA-4 (91).”
BackgroundLim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Darnell, E. P., Mooradian, M. J., Baruch, E. N., Yilmaz, M., & Reynolds, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0897-9 · Cited by 380
Xu, F., Liu, J., Liu, D., Liu, B., Wang, M., Hu, Z., Du, X., Tang, L., & He, F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2690 · Cited by 373
Interleukin-6 as a Therapeutic Target
Rossi, J.-F., Lu, Z.-Y., Jourdan, M., & Klein, B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2291 · Cited by 366
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun-Vignes, B., Mammen, A., Moslehi, J. J., & Salem, J.-E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0617-x · Cited by 366
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351 · cited 2×
“Frontiers in Immunology 05 breaking of autoimmune tolerance or the body becoming more sensitive to antigen recognition and attacking its own tissues (54).”
BackgroundTocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331 · cited 2×
“Study has shown that the application of tocilizumab in steroid-refractory irAEs alleviates clinical symptoms and significantly reduces treatment costs compared to infliximab (140).”
BackgroundLozano, A. X., Chaudhuri, A. A., Nene, A., Bacchiocchi, A., Earland, N., Vesely, M. D., Usmani, A., Turner, B. E., Steen, C. B., Luca, B. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01623-z · Cited by 314
CTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 297
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Sullivan, R. J., & Weber, J. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 291
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze-Koops, H., Choy, E. H., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 290
PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200389 · Cited by 288 · cited 2×
“Deletion of CTLA-4 and PD-1 lead to autoimmune myocarditis (56, 101, 102).”
BackgroundSystematic review: colitis associated with anti‐CTLA‐4 therapy
Gupta, A., De Felice, K. M., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 273
Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review
Marini, A., Bernardini, A., Gigli, G. L., Valente, M., Muñiz-Castrillo, S., Honnorat, J., & Vogrig, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011795 · Cited by 273
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Wang, J., Okazaki, I.-M., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., Hiai, H., Honjo, T., & Okazaki, T. (2010) · International Immunology · doi:10.1093/intimm/dxq026 · Cited by 270
Larkin, J., Chmielowski, B., Lao, C. D., Hodi, F. S., Sharfman, W., Weber, J., Suijkerbuijk, K. P. M., Azevedo, S., Li, H., Reshef, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0487 · Cited by 267
Enterocolitis due to immune checkpoint inhibitors: a systematic review
Soularue, E., Lepage, P., Colombel, J. F., Coutzac, C., Faleck, D., Marthey, L., Collins, M., Chaput, N., Robert, C., & Carbonnel, F. (2018) · Gut · doi:10.1136/gutjnl-2018-316948 · Cited by 264
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
Peeraphatdit, T. (., Wang, J., Odenwald, M. A., Hu, S., Hart, J., & Charlton, M. R. (2020) · Hepatology · doi:10.1002/hep.31227 · Cited by 264
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Hemon, P., Jean-Louis, F., Ramgolam, K., Brignone, C., Viguier, M., Bachelez, H., Triebel, F., Charron, D., Aoudjit, F., Al-Daccak, R., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002050 · Cited by 252
Laino, A. S., Woods, D., Vassallo, M., Qian, X., Tang, H., Wind-Rotolo, M., & Weber, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000842 · Cited by 249
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 246
Chen, T. W., Razak, A. R., Bedard, P. L., Siu, L. L., & Hansen, A. R. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv182 · Cited by 243
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234 · cited 1×
“Frontiers in Immunology 07 risk of colitis associated with ICIs (79).”
BackgroundWang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
Cutaneous adverse effects of the immune checkpoint inhibitors
Collins, L. K., Chapman, M. S., Carter, J. B., & Samie, F. H. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.001 · Cited by 219
Chocarro, L., Blanco, E., Zuazo, M., Arasanz, H., Bocanegra, A., Fernández-Rubio, L., Morente, P., Fernández-Hinojal, G., Echaide, M., Garnica, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105282 · Cited by 216
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Muir, C. A., Clifton-Bligh, R. J., Long, G. V., Scolyer, R. A., Lo, S. N., Carlino, M. S., Tsang, V. H. M., & Menzies, A. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab263 · Cited by 212
Willsmore, Z. N., Coumbe, B. G. T., Crescioli, S., Reci, S., Gupta, A., Harris, R. J., Chenoweth, A., Chauhan, J., Bax, H. J., McCraw, A., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202048747 · Cited by 204
Valpione, S., Pasquali, S., Campana, L. G., Piccin, L., Mocellin, S., Pigozzo, J., & Chiarion-Sileni, V. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1467-x · Cited by 201 · cited 1×
“There is also evidence that lower baseline IL-6 levels are significantly associated with the development of irAEs (62).”
BackgroundReversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Esfahani, K., & Miller, W. H. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1703047 · Cited by 200
Abatacept: A Review in Rheumatoid Arthritis
Blair, H. A., & Deeks, E. D. (2017) · Drugs · doi:10.1007/s40265-017-0775-4 · Cited by 199
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0245 · Cited by 191 · cited 1×
“TPOAb and anti-thyroglobulin antibodies (TGAb) were the most common (60).”
BackgroundImmune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis
Akturk, H. K., Kahramangil, D., Sarwal, A., Hoffecker, L., Murad, M. H., & Michels, A. W. (2019) · Diabetic Medicine · doi:10.1111/dme.14050 · Cited by 188
TNF in the era of immune checkpoint inhibitors: friend or foe?
Chen, A. Y., Wolchok, J. D., & Bass, A. R. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00584-4 · Cited by 183
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis
Rubio‐Infante, N., Ramírez‐Flores, Y. A., Castillo, E. C., Lozano, O., García‐Rivas, G., & Torre‐Amione, G. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2289 · Cited by 179
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
Ellis, S. R., Vierra, A. T., Millsop, J. W., Lacouture, M. E., & Kiuru, M. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.105 · Cited by 175
Shahabi, V., Berman, D., Chasalow, S. D., Wang, L., Tsuchihashi, Z., Hu, B., Panting, L., Jure-Kunkel, M., & Ji, R.-R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-75 · Cited by 173
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy
Michel, L., Helfrich, I., Hendgen-Cotta, U. B., Mincu, R.-I., Korste, S., Mrotzek, S. M., Spomer, A., Odersky, A., Rischpler, C., Herrmann, K., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab430 · Cited by 168
Merola, J. F., Landewé, R., McInnes, I. B., Mease, P. J., Ritchlin, C. T., Tanaka, Y., Asahina, A., Behrens, F., Gladman, D. D., Gossec, L., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02303-0 · Cited by 168
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
Kang, C.-W., Dutta, A., Chang, L.-Y., Mahalingam, J., Lin, Y.-C., Chiang, J.-M., Hsu, C.-Y., Huang, C.-T., Su, W.-T., Chu, Y.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep15659 · Cited by 163
The clinical utility of inhibiting CD28‐mediated costimulation
Linsley, P. S., & Nadler, S. G. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00780.x · Cited by 162
Cutaneous adverse events caused by immune checkpoint inhibitors
Quach, H. T., Johnson, D. B., LeBoeuf, N. R., Zwerner, J. P., & Dewan, A. K. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.054 · Cited by 160
Sloan, E. A., Ring, K. L., Willis, B. C., Modesitt, S. C., & Mills, A. M. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000783 · Cited by 156
Wang, F., Qin, S., Sun, X., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00886-2 · Cited by 153
Geisler, B. P., Raad, R. A., Esaian, D., Sharon, E., & Schwartz, D. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0048-2 · Cited by 144
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Qian, W., Zhao, M., Wang, R., & Li, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01161-8 · Cited by 144
Immune checkpoint inhibitor-related hepatotoxicity: A review
Remash, D., Prince, D. S., McKenzie, C. A., Strasser, S. I., Kao, S., & Liu, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5376 · Cited by 133
Interplay between Immune Checkpoint Proteins and Cellular Metabolism
Lim, S., Phillips, J. B., da Silva, L. M., Zhou, M., Fodstad, Ø., Owen, L. B., & Tan, M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1647 · Cited by 118
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Kang, J. H., Bluestone, J. A., & Young, A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.006 · Cited by 118
Lee, D. J., Lee, H. J., Farmer, J. R., & Reynolds, K. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01530-2 · Cited by 108
Waight, J. D., Chand, D., Dietrich, S., Gombos, R., Horn, T., Gonzalez, A. M., Manrique, M., Swiech, L., Morin, B., Brittsan, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.005 · Cited by 104
Semper, H., Muehlberg, F. L., Schulz‐Menger, J., Allewelt, M., & Grohé, C. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.025 · Cited by 100
Campochiaro, C., Farina, N., Tomelleri, A., Ferrara, R., Lazzari, C., Luca, G. D. D., Bulotta, A., Signorelli, D., Palmisano, A., Vignale, D., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.07.016 · Cited by 99
Mechanisms of immune checkpoint inhibitor-mediated liver injury
Shojaie, L., Ali, M., Iorga, A., & Dara, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.003 · Cited by 98
Hemophilia A Induced by Ipilimumab
Delyon, J., Mateus, C., & Lambert, T. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1110923 · Cited by 98
Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
Yang, L., Ning, Q., & Tang, S. (2022) · Journal of Immunology Research · doi:10.1155/2022/8052212 · Cited by 98
Both PD-1 Ligands Protect the Kidney from Ischemia Reperfusion Injury
Jaworska, K., Ratajczak, J., Huang, L., Whalen, K., Yang, M., Stevens, B. K., & Kinsey, G. R. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400497 · Cited by 95
Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
Reddy, H. G., Schneider, B. J., & Tai, A. W. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0049-9 · Cited by 94
Immune checkpoint inhibitors and risk of type 1 diabetes
Chen, X., Affinati, A. H., Lee, Y., Turcu, A. F., Henry, N. L., Schiopu, E., Qin, A., Othus, M., Clauw, D., Ramnath, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2213 · Cited by 93
A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
Liao, D., Wang, M., Liao, Y., Li, J., & Niu, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00609 · Cited by 91
Immune checkpoint inhibitor-related thyroid dysfunction
Iwama, S., Kobayashi, T., Yasuda, Y., & Arima, H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101660 · Cited by 85
Horisberger, A., La Rosa, S., Zurcher, J.-P., Zimmermann, S., Spertini, F., Coukos, G., & Obeid, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0481-0 · Cited by 81
Hurwitz, A. A., Sullivan, T. J., Sobel, R. A., & Allison, J. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042684699 · Cited by 79
Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
Rajha, E., Chaftari, P. S., Kamal, M. J., Maamari, J., Chaftari, C. P., & Yeung, S. J. (2019) · Gastroenterology report · doi:10.1093/gastro/goz065 · Cited by 76
Scarsi, M., Paolini, L., Ricotta, D., Pedrini, A., Piantoni, S., Caimi, L., Tincani, A., & Airó, P. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130905 · Cited by 73
Patil, P. A., & Zhang, X. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0070-ra · Cited by 68
Thyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 68
Nadelmann, E. R., Yeh, J., & Chen, S. T. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4318 · Cited by 64
Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
Hu, Z. I., Link, V. M., Lima-Junior, D. S., Delaleu, J., Bouladoux, N. J., Han, S., Collins, N., & Belkaid, Y. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200348119 · Cited by 61
Moi, L., Bouchaab, H., Mederos, N., Nguyen-Ngoc, T., Perreau, M., Fenwick, C., Vaucher, J., Sempoux, C., Peters, S., & Obeid, M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.007 · Cited by 52
Gene of the month: lymphocyte-activation gene 3 (LAG-3)
Lythgoe, M. P., Liu, D., Annels, N. E., Krell, J., & Frampton, A. E. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207517 · Cited by 52
Liao, W., Zheng, H., Wu, S., Zhang, Y., Wang, W., Zhang, Z., Zhou, C., Wu, H., & Min, J. (2017) · American Journal of Nephrology · doi:10.1159/000480641 · Cited by 50
Nastoupil, L. J., Chin, C. K., Westin, J. R., Fowler, N. H., Samaniego, F., Cheng, X., Ma, M. C. J., Wang, Z., Chu, F., Dsouza, L., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006240 · Cited by 50
Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy
Rajapakse, P., & Andanamala, H. (2022) · World Journal of Oncology · doi:10.14740/wjon1464 · Cited by 48
Lin, J. S., Wang, D. Y., Mamlouk, O., Glass, W. F., Abdelrahim, M., Yee, C., & Abudayyeh, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001287 · Cited by 47
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
Olsen, T. A., Zhuang, T., Caulfield, S. E., Martini, D. J., Brown, J. T., Carthon, B. C., Küçük, Ö., Harris, W. B., Bilen, M. A., & Nazha, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.779915 · Cited by 46
Qi, Y., Chen, L., Liu, Q., Kong, X., Fang, Y., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563258 · Cited by 44
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Ruggiero, A., Potestio, L., Camela, E., Fabbrocini, G., & Megna, M. (2022) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s367744 · Cited by 44
Rose, L. M., DeBerg, H. A., Vishnu, P., Frankel, J., Manjunath, A. B., Flores, J. P., & Aboulafia, D. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.570752 · Cited by 40
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 37
Liu, X., Wu, W., Fang, L., Liu, Y., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922782 · Cited by 37
Therapeutic Development of Immune Checkpoint Inhibitors
Wang, J., Yang, T., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_23 · Cited by 35
Type 1 diabetes related to immune checkpoint inhibitors
Tachibana, M., & Imagawa, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101657 · Cited by 35
Diabetes mellitus induced by immune checkpoint inhibitors
Zheng, Z., Liu, Y., Yang, J., Tan, C., Zhou, L., Wang, X., Li, X., Zhang, S., Chen, Y., & Liu, X. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3366 · Cited by 34
Immune Checkpoint Blockade and Skin Toxicity Pathogenesis
Ma, B., & Anandasabapathy, N. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.06.040 · Cited by 34
Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
Barclay, J., Creswell, J., & León, J. (2018) · PubMed · Cited by 33
Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
Rocha, M., de Sousa, J. C., Salgado, M., Araújo, A., & Pedroto, I. (2018) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000494569 · Cited by 31
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
Cuyàs, E., Verdura, S., Martín-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 30
Yamada, K., Sawada, T., Nakamura, M., Yamamura, T., Maeda, K., Ishikawa, E., Iida, T., Mizutani, Y., Kakushima, N., Ishikawa, T., et al. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i41.7190 · Cited by 30
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
Zhou, N., Velez, M. A., Bachrach, B., Gukasyan, J., Fares, C. M., Cummings, A. L., Lind-Lebuffe, J. P., Akingbemi, W. O., Li, D., Brodrick, P. M., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.009 · Cited by 20
Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
Verma, N., Jaffer, M., Sharda, E., Piña, Y., Ramsakal, A., Vogelbaum, M., Forsyth, P. A., Peguero, E. N., & Mokhtari, S. (2021) · Cureus · doi:10.7759/cureus.16337 · Cited by 19
Manos, K., Chong, G., Keane, C., Lee, S.-T., Smith, C. D., Churilov, L. P., McKendrick, J. J., Renwick, W. E. P., Blombery, P. A., Burgess, M. L., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01863-7 · Cited by 16
Chen, C.-Y., Huang, C., Chen, W., Huang, M., & Wei, Y.-F. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108848 · Cited by 15
Management of gastrointestinal adverse events induced by immune‐checkpoint inhibitors
Wang, Z., & Shen, L. (2018) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.12.001 · Cited by 14
Cui, C., Deng, L., Wang, W., Ren, X., Wang, Y., & Cui, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.941079 · Cited by 12
Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
Catalano, M., Roviello, G., Galli, I. C., Santi, R., & Nesi, G. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1014257 · Cited by 12
Mi, Z., Zhang, Y., Feng, Z., Liu, J., Wu, J., Tan, H., Ma, X., Liu, Z., & Rong, P. (2022) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2022.2131354 · Cited by 10
Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives
Farshidpour, M., & Hutson, W. R. (2022) · Middle East Journal of Digestive Diseases · doi:10.34172/mejdd.2022.279 · Cited by 9
Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors
Iacovelli, R., Ciccarese, C., Fantinel, E., Bimbatti, D., Romano, M., Porcaro, A. B., Siracusano, S., Mazzarotto, R., Artibani, W., & Tortora, G. (2017) · Journal of Onco-Nephrology · doi:10.5301/jo-n.5000019 · Cited by 6
Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report
Fletcher, J. A., Bird, R. J., McLean, A. J. W., O'Byrne, K. J., & Xu, W. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100409 · Cited by 5
Cited by
Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
Metadata
- Authors
- Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-05-25
- Volume
- 14
- Pages
- 1167975-1167975
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4378232556
- Cited by
- 446
- References
- 151
- FWCI
- 45.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.